Surajuddeen Muhammad

Surajuddeen Muhammad

Auto-generated profile, based on publicly available information

Surajuddeen Muhammad

Faculty of Veterinary Medicine, Ahmadu Bello University, Kaduna, Nigeria

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Closed access
PDF file
Mustapha MohammedMustapha Mohammed
Mustapha Mohammed
NKNarendar Kumar
Narendar Kumar
MZMohammed Zawiah
Mohammed Zawiah
FAFahmi Y. Al-Ashwal
Fahmi Y. Al-Ashwal
ABAuwal Adam Bala
Auwal Adam Bala
Abubakar Sha'abanAbubakar Sha'aban
Abubakar Sha'aban

13 October 2020 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Open access
PDF file
Mustapha MohammedMustapha Mohammed
Mustapha Mohammed
SMSurajuddeen Muhammad
Surajuddeen Muhammad
FMFatima Zaji Mohammed
Fatima Zaji Mohammed
SMSagir Mustapha
Sagir Mustapha
Abubakar Sha'abanAbubakar Sha'aban
Abubakar Sha'aban
HZHadzliana Zainal
Hadzliana Zainal
Background The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in China and later spread rapidly to other parts of the world, including Africa. Africa was projected to be devastated by COVID-19. There is currently limited data regarding regional predictors of mortality among patients with COVID-19. This study aimed to evaluate the independent risk factors associated with mortality among patients with COVID-19 in Africa. Methods A total of 1028 confirmed cases of COVID-19 from Africa with definite survival outcomes were identified retrospectively from an open-access individual-level worldwide COVID-19 database. The live version of the dataset is available at https://github.com/beoutbreakprepared/nCoV2019. Multivariable logistic regression was conducted to determine the risk factors that independently predict mortality among patients with COVID-19 in Africa. Results Of the 1028 cases included in study, 432 (42.0%) were females with a median (interquartile range, IQR) age of 50 (24) years. Older age (adjusted odds ratio {aOR} 1.06; [95% confidence intervals {95% CI}, 1.04–1.08]), presence of chronic disease (aOR 9.63; [95% CI, 3.84–24.15]), travel history (aOR 2.44; [95% CI, 1.26–4.72]), as well as locations of Central Africa (aOR 0.14; [95% CI, 0.03–0.72]) and West Africa (aOR 0.12; [95% CI, 0.04–0.32]) were identified as the independent risk factors significantly associated with increased mortality among the patients with COVID-19. Conclusions The COVID-19 pandemic is evolving gradually in Africa. Among patients with COVID-19 in Africa, older age, presence of chronic disease, travel history, and the locations of Central Africa and West Africa were associated with increased mortality. A regional response should prioritize strategies that will protect these populations. Also, conducting a further in-depth study could provide more insights into additional factors predictive of mortality in COVID-19 patients.

19 April 2022 in Toxicological Research
Verified
Journal Article
Closed access
PDF file
MAMubarak Hussaini Ahmad
Mubarak Hussaini Ahmad
AZAbdulkadir Umar Zezi
Abdulkadir Umar Zezi
SASherifat Bola Anafi
Sherifat Bola Anafi
OAOmar Alshargi
Omar Alshargi
Mustapha MohammedMustapha Mohammed
Mustapha Mohammed
IAIbrahim Jatau Abubakar
Ibrahim Jatau Abubakar

5 June 2021 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
MAMubarak Hussaini Ahmad
Mubarak Hussaini Ahmad
IAIbrahim Jatau Abubakar
Ibrahim Jatau Abubakar
OAOmar Alshargi
Omar Alshargi
SJSa’aDatu Muhammad Julde
Sa’aDatu Muhammad Julde
Mustapha MohammedMustapha Mohammed
Mustapha Mohammed
AUAbba Musab Usman
Abba Musab Usman
Background: The plant Olax subscorpioidea Oliv (Olacaceae) is a shrub that is widely available in Africa. It has been used in traditional medicine to treat various diseases including asthma, pain, inflammation, gastrointestinal and central nervous system (CNS) disorders, cough, diabetes mellitus, cancer, infectious diseases, hepatic diseases, and many other diseases. Several phytochemical and pharmacological investigations were conducted on this plant. However, comprehensive information on this medicinally important plant is not available in the literature. Therefore, in this review, we aimed to provide comprehensive and critical information on all the reported ethnomedicinal uses, phytochemistry, pharmacological activities, and potential toxicity of Olax subscorpioidea to highlight its therapeutic potentials based on traditional usage and identify research gaps as a basis for further investigations to develop novel therapeutic compounds. Main body: The available information about the plant was retrieved from the online bibliographic databases (PubMed and Google Scholar) and published PhD dissertation using the search terms Olax subscorpioidea, traditional uses, ethnomedicinal uses, phytochemistry, pharmacology, toxicology, and safety. Phytochemical studies have shown that the plant contains several bioactive compounds such as rutin, morin, quercetin, caffeic acid, santalbic acid, n-hexadecanoic acid, squalene, nonacosane, hentriacontane, and many more compounds. Also, pharmacological investigations revealed that Olax subscorpioidea has antidepressant, antiepileptic, anti-Alzheimer’s, cytotoxic, antioxidant, antihyperlipidemic, analgesic, antiinflammatory, antiarthritic, antidiabetic, anticancer, antiulcer, antimicrobial, hepatoprotective, apoptotic, antiprotease, and other CNS effects. Conclusion: Several pharmacological studies on Olax subscorpioidea have established its ethnopharmacological uses. However, there are limited phytochemical and pharmacological studies to validate other folkloric claims of the plant. Therefore, extensive phytochemical and further pre-clinical efficacy and safety evaluations to fully establish its therapeutic potentials and elucidate its mechanisms of pharmacological actions could be necessary. Graphical

13 February 2025 in Health Science Reports
Verified
Journal Article
Open access
Mustapha MohammedMustapha Mohammed
Mustapha Mohammed
HZHadzliana Zainal
Hadzliana Zainal
SOSiew Chin Ong
Siew Chin Ong
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
FAFatimatuzzahra’ Abd Aziz
Fatimatuzzahra’ Abd Aziz
ZAZariah A. Aziz
Zariah A. Aziz
Background and Aims: There is a lack of population‐based studies focusing on guideline‐based prognostic models for stroke. This study aimed to develop and validate a prognostic model that predicts mortality following a first‐ever acute ischemic stroke.Methods: The study included 899 adult patients ( ≥ 18 years) with confirmed diagnosis of first‐ever acute ischemic stroke enrolled in the Malaysian National Stroke Registry (NSR) from January 2009 to December 2019. The primary outcome was mortality within 90 days post‐stroke (266 events [29.6%]). The prognostic model was developed using logistic regression (75%, n = 674) and internally validated (25%, n = 225). Model performance was assessed using discrimination (area under the curve (AUC]) and calibration (Hosmer‐Lemeshow test [HL]).Results: The final model includes factors associated with increased risk of mortality, such as age (adjusted odds ratio, aOR 1.06 [95% confidence interval, CI 1.03, 1.10; p < 0.001]), National Institutes of Health Stroke Scale (NIHSS) score aOR 1.08 (95% CI 1.08, 1.13; p = 0.004), and diabetes aOR 2.29 (95% CI 1.20, 4.37; p = 0.012). The protective factors were antiplatelet within 48 h. aOR 0.40 (95% CI 0.19, 0.81; p = 0.01), dysphagia screening aOR 0.30 (95% CI 0.15, 0.61; p = 0.001), antiplatelets upon discharge aOR 0.17 (95% CI 0.08, 0.35; p < 0.001), lipid‐lowering therapy aOR 0.37 (95% CI 0.17, 0.82; p = 0.01), stroke education aOR 0.02 (95% CI 0.01, 0.05; p < 0.001) and rehabilitation aOR 0.08 (95% CI 0.04, 0.16; p < 0.001). The model demonstrated excellent performance (discrimination [AUC = 0.94] and calibration [HL, X2 p = 0.63]).Conclusion: The study developed a validated prognostic model that excellently predicts mortality after a first‐ever acute ischemic stroke with potential clinical utility in acute stroke care decision‐making. The predictors could be valuable for creating risk calculators and aiding healthcare providers and patients in making well‐informed clinical decisions during the stroke care process.

26 March 2026 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Mustapha MohammedMustapha Mohammed
Mustapha Mohammed
HZHadzliana Zainal
Hadzliana Zainal
SOSiew Chin Ong
Siew Chin Ong
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
FAFatimatuzzahra’ Abd Aziz
Fatimatuzzahra’ Abd Aziz
ZAZariah A. Aziz
Zariah A. Aziz
Background: There is limited evidence on prognostic models that incorporate clinical guideline recommendations during the acute management of ischemic stroke. This study aimed to develop and validate clinical guideline-based prognostic models of functional disability following a first-ever acute ischemic stroke. Methods: A multicenter retrospective cohort study was conducted using data from 899 adult patients (aged 18 years or older) with a first-ever acute ischemic stroke, and enrolled in the Malaysian National Stroke Registry (NSR) between January 2009 and December 2019. The primary outcome was functional disability at three months post-discharge, defined as a modified Rankin Scale (mRS) score of 3 to 5. A multivariable logistic regression model was developed using random sampling data splitted into two cohorts: the development ( n = 674; 75%) and the internal validation ( n = 225; 25%). Model performance was evaluated by discrimination [area under the curve (AUC)] and calibration [Hosmer–Lemeshow (HL) test]. Results: The final prognostic model showed factors associated with increased risk of functional disability include age [adjusted odds ratio (aOR) 1.02, 95% CI 1.00–1.04, p = 0.024], female gender [aOR 1.54, 95% CI 1.06–2.23, p = 0.024], and diabetes [aOR 1.66, 95% CI 1.15–2.40, p = 0.007]. While those factors associated with decreased risk of disability include posterior circulation infarct (POCI) [aOR 0.38, 95% CI 0.18–0.78, p = 0.009], and adherence to key performance indicators (KPIs); antiplatelet therapy [aOR 0.48, 95% CI 0.29–0.80, p = 0.005], lipid-lowering therapy [aOR 0.56, 95% CI 0.37–0.83, p = 0.004], stroke education [aOR 0.09, 95% CI 0.05–0.16, p < 0.001], and rehabilitation [aOR 0.43, 95% CI 0.29–0.64, p < 0.001]. The fitted model demonstrated good discrimination (AUC: 0.803; 95% CI, 0.78–0.83 for development, and 0.777; 95% CI, 0.75–0.81 for validation) and calibration (HL test: p = 0.473 for development, p = 0.967 for validation). Conclusion: A clinical guideline-guided prognostic model of functional disability following a first-ever acute ischemic stroke was successfully developed and validated, demonstrating strong performance and potential clinical relevance. This model can help clinicians predict stroke outcomes, guide informed clinical decision-making, and support the development of personalized stroke care.